Healthcare

What to do when central bankers tell you to cut risk.
A lower price means more value for this high-quality stock.

Take a Yellen Opportunity Real Money Pro($)

There's a great entry point in Celgene at $84.
It is preserving its Copaxone franchise, and the executive changes are good news.
Cheap money and greed from the Allergan bidder's side are strong incentives.
A wave of M&A in the health sector makes sense.
Forget marijuana, there's a more basic reason to be bearish.
The stock seems liable to reenter its uptrend, so here's how to play it.
Borrowing a page from a master investor's playbook.
I doubt its rally stalls here

Columnist Conversations

Using this year's estimate to make a P/E is pretty standard. Basing a multiple on 2015's projected EPS is not ...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.